EU agency issues new warnings for Parkinson's drugs

LONDON, June 26 (Reuters) - The European Medicines Agency has issued new warnings related to the risk of fibrosis for five ergo-derived dopamine agonists to treat Parkinson's disease, the drugs watchdog said on Thursday.

The class of drugs include Parlodel, known generically as bromocriptine; Dostinex and Cabaser, or cabergoline; dihydroergocryptine; Dopergin, or lisuride; and Celance, or pergolide.

Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.

(Reporting by Michael Kahn)